RSS-Feed abonnieren
PDF herunterladen
DOI: 10.1055/s-0045-1806855
2025 Eberhard F. Mammen Award Announcements: Part I—Most Popular Articles
Welcome to the latest of our Eberhard F Mammen award announcements. As noted in previous editorials ([Table 1]), Thieme, the publisher of Seminars in Thrombosis and Hemostasis (STH), has created the “Eberhard F Mammen Excellence in Thrombosis and Hemostasis Awards” in honor of Eberhard Mammen ([Fig. 1]), and in recognition of his contribution to this field and to the journal that he both founded and steered for over three decades. These awards began in 2009, under two categories, “Most Popular Article Awards” and “Young Investigator Awards.” Accordingly, 2025 represents 17 years of award presentations ([Table 1]). Current details and conditions of the award can be summarized as:
-
Most popular article awards: Awarded to the authors of the most popular articles published in STH in the preceding 2 years as captured in the preceding year. The awards are determined by the Editor in Chief on the basis of user statistics from the publisher Thieme e-Journals. Prefaces, Errata, Letters to the Editor, Editorials, Commentaries, and previous award-winning articles are excluded from further consideration of these awards, which currently comprise two categories: one for “Free Access” articles, and another for a “General Category.” There are two major cash prizes of US$1,000 for each category. In addition, winners of the “General Category” awards are granted “Free Access” status for these articles thereafter.
-
Young investigator awards: Best presentation or meeting abstract by a young investigator—as presented or delivered to an international or large regional meeting on a topic related to the fields of thrombosis and hemostasis, and whose subject matter is determined to be in the spirit of Dr Mammen. Up to six cash prizes of US$1,000 in any year. There are some additional considerations and conditions for the award, and awardees are expected to prepare a review or other paper related to the topic of their presentation (or as otherwise agreed) for publication in STH. Previous award winners are excluded from a second award to enable more individuals to be recognized. After nominations are received, the awardees are selected by a vote of the Senior Editors of STH. Any potential conflicts of interest are managed by first identifying these, and then excluding those with potential conflicts from voting. Finally, given historical coronavirus disease 2019 (COVID-19) concerns, some meetings are still held as virtual or hybrid meetings, and accordingly, these meeting presentations can also be considered for the award.
Further details of the awards and the award winners are posted online (<https://www.thieme-connect.com/products/ejournals/journal/10.1055/s-00000077>), and previous award winner announcements are also available in print ([Table 1]).
It is therefore with great pleasure that we would like to announce the latest winners of the 2025 Eberhard F Mammen awards for the most popular articles from STH, as downloaded in 2024 and as published in the period of 2023 to 2024 inclusive.
Publikationsverlauf
Artikel online veröffentlicht:
25. März 2025
© 2025. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Kruger A, Joffe D, Lloyd-Jones G. et al. Vascular pathogenesis in acute and long COVID: current insights and therapeutic outlook. Semin Thromb Hemost 2024; 51: 256-271
- 2 Warkentin TE, Greinacher A. Laboratory testing for heparin-induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia antibodies: a narrative review. Semin Thromb Hemost 2023; 49 (06) 621-633
- 3 Gosselin RC, Castellone D, Dorgalaleh A. et al. International Council for Standardization in Haematology guidance for new lot verification of coagulation reagents, calibrators, and controls. Semin Thromb Hemost 2024; 50 (08) 1091-1102
- 4 Bowyer AE, Gosselin RC. Factor VIII and factor IX activity measurements for hemophilia diagnosis and related treatments. Semin Thromb Hemost 2023; 49 (06) 609-620
- 5 Luijten D, de Jong CMM, Ninaber MK, Spruit MA, Huisman MV, Klok FA. Post-pulmonary embolism syndrome and functional outcomes after acute pulmonary embolism. Semin Thromb Hemost 2023; 49 (08) 848-860
- 6 Yong BSJ, Ling RR, Li R. et al. Pharmacotherapy for venous thromboprophylaxis following total hip or knee arthroplasty: a systematic review and network meta-analysis. Semin Thromb Hemost 2024; 51: 290-300
- 7 Favaloro EJ. The role of the von Willebrand factor collagen-binding assay (VWF:CB) in the diagnosis and treatment of von Willebrand disease (VWD) and way beyond: a comprehensive 36-year history. Semin Thromb Hemost 2024; 50 (01) 43-80
- 8 Moore GW. Thrombophilia screening: not so straightforward. Semin Thromb Hemost 2024; 50 (08) 1131-1152
- 9 Ortega-Paz L, Talasaz AH, Sadeghipour P. et al. COVID-19-associated pulmonary embolism: review of the pathophysiology, epidemiology, prevention, diagnosis, and treatment. Semin Thromb Hemost 2023; 49 (08) 816-832
- 10 Talasaz AH, McGonagle B, HajiQasemi M. et al. Pharmacokinetic and pharmacodynamic interactions between food or herbal products and oral anticoagulants: evidence review, practical recommendations, and knowledge gaps. Semin Thromb Hemost 2024; (e-pub ahead of print).
- 11 Barcellona D, Marongiu F, Grandone E. Contraceptives and thrombosis: an intertwined revolutionary road. Semin Thromb Hemost 2024; 50 (01) 91-95
- 12 Selvadurai MV, Favaloro EJ, Chen VM. Mechanisms of thrombosis in heparin-induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia. Semin Thromb Hemost 2023; 49 (05) 444-452
- 13 Iba T, Wada H, Levy JH. Platelet activation and thrombosis in COVID-19. Semin Thromb Hemost 2023; 49 (01) 55-61
- 14 Aguirre Del-Pino R, Monahan RC, Huizinga TWJ, Eikenboom J, Steup-Beekman GM. Risk factors for antiphospholipid antibodies and antiphospholipid syndrome. Semin Thromb Hemost 2024; 50 (06) 817-828
- 15 Favaloro EJ. Evolution of hemostasis testing: a personal reflection covering over 40 years of history. Semin Thromb Hemost 2024; 50 (01) 8-25
- 16 Pretorius E, Kell DB. A perspective on how fibrinaloid microclots and platelet pathology may be applied in clinical investigations. Semin Thromb Hemost 2024; 50 (04) 537-551
- 17 Trujillo-Santos J, Demelo-Rodríguez P, Bravo de Laguna-Taboada A. et al; Working Group on for the Consensus on Venous Stenting. Optimizing venous stenting: consensus recommendations for enhanced management of lower extremity deep vein thrombosis. Semin Thromb Hemost 2024; 50 (06) 883-893
- 18 Mabrouk M, Guessous F, Naya A, Merhi Y, Zaid Y. The pathophysiological role of platelet-derived extracellular vesicles. Semin Thromb Hemost 2023; 49 (03) 279-283
- 19 Bissola AL, Zhang Y, Cranstone M. et al. Evaluating diagnostic algorithms for heparin-induced thrombocytopenia using two combined automated rapid immunoassays. Semin Thromb Hemost 2024; 50 (08) 1123-1130
- 20 Franchini M, Cappello E, Valdiserra G. et al. Investigating a signal of acquired hemophilia associated with COVID-19 vaccination: a systematic case review. Semin Thromb Hemost 2023; 49 (01) 15-26
- 21 Buso G, Mazzolai L, Rueda-Camino JA. et al; RIETE Investigators. Pulmonary embolism in patients with COVID-19: comparison between different care settings. Semin Thromb Hemost 2023; 49 (01) 34-46
- 22 Lippi G, Favaloro EJ. What we know (and do not know) regarding the pathogenesis of pulmonary thrombosis in COVID-19. Semin Thromb Hemost 2023; 49 (01) 27-33
- 23 Ichinose A, Osaki T, Souri M. Diagnosis and treatment of autoimmune acquired coagulation factor deficiencies: an evidence-based review of Japanese practice. Semin Thromb Hemost 2024; (e-pub ahead of print).
- 24 Al-Ghafry M, Abou-Ismail MY, Acharya SS. Inherited disorders of the fibrinolytic pathway: pathogenic phenotypes and diagnostic considerations of extremely rare disorders. Semin Thromb Hemost 2025; 51: 225-233
- 25 Rizk JG, Gupta A, Lazo Jr JG. et al. To anticoagulate or not to anticoagulate in COVID-19: lessons after 2 years. Semin Thromb Hemost 2023; 49 (01) 62-72
- 26 Arachchillage DJ, Kitchen S. Pleiotropic effects of heparin and its monitoring in the clinical practice. Semin Thromb Hemost 2024; 50 (08) 1153-1162
- 27 Arcani R, Cauchois R, Suchon P. et al. “True” antiphospholipid syndrome in COVID-19: contribution of the follow-up of antiphospholipid autoantibodies. Semin Thromb Hemost 2023; 49 (01) 97-102
- 28 Candeloro M, Schulman S. Arterial thrombotic events in hospitalized COVID-19 patients: a short review and meta-analysis. Semin Thromb Hemost 2023; 49 (01) 47-54
- 29 Spiezia L, Campello E, Tormene D, Simioni P. Venous thromboembolism in children: the rivaroxaban experience. Semin Thromb Hemost 2024; 50 (06) 866-872
- 30 Warkentin TE. Limb ischemic necrosis secondary to microvascular thrombosis: a brief historical review. Semin Thromb Hemost 2024; 50 (05) 760-772
- 31 Bartlett R, Arachichilage DJ, Chitlur M. et al. The history of extracorporeal membrane oxygenation and the development of extracorporeal membrane oxygenation anticoagulation. Semin Thromb Hemost 2024; 50 (01) 81-90
- 32 Costamagna G, Navi BB, Beyeler M, Hottinger AF, Alberio L, Michel P. Ischemic stroke in cancer: mechanisms, biomarkers, and implications for treatment. Semin Thromb Hemost 2024; 50 (03) 342-359
- 33 Morrow GB, Mutch NJ. Past, present, and future perspectives of plasminogen activator inhibitor 1 (PAI-1). Semin Thromb Hemost 2023; 49 (03) 305-313
- 34 Larsen JB, Hvas AM, Hojbjerg JA. Platelet function testing: update and future directions. Semin Thromb Hemost 2023; 49 (06) 600-608
- 35 Moser MM, Schoergenhofer C, Jilma B. Progress in von Willebrand disease treatment: evolution towards newer therapies. Semin Thromb Hemost 2024; 50 (05) 720-732
- 36 Chandran R, Tohit ERM, Stanslas J, Salim N, Mahmood TMT, Rajagopal M. Shifting paradigms and arising concerns in severe hemophilia A treatment. Semin Thromb Hemost 2024; 50 (05) 695-713
- 37 Rashedi S, Greason CM, Sadeghipour P. et al. Fibrinolytic agents in thromboembolic diseases: historical perspectives and approved indications. Semin Thromb Hemost 2024; 50 (05) 773-789
- 38 Adcock DM, Moore GW, Montalvão SL, Kershaw G, Gosselin RC. Activated partial thromboplastin time and prothrombin time mixing studies: current state of the art. Semin Thromb Hemost 2023; 49 (06) 571-579
- 39 Bikdeli B, Sadeghipour P, Lou J. et al. Developmental or procedural vena cava interruption and venous thromboembolism: a review. Semin Thromb Hemost 2024; 50 (06) 851-865
- 40 Pruthi RK, Chen D. The use of bypassing treatment strategies in hemophilia and their effect on laboratory testing. Semin Thromb Hemost 2023; 49 (06) 651-660
- 41 Levy-Mendelovich S, Cohen O, Klang E, Kenet G. 50 years of pediatric hemostasis: knowledge, diagnosis, and treatment. Semin Thromb Hemost 2023; 49 (03) 217-224
- 42 Betts MB, Liu X, Junqueira DR. et al. Risk of venous thromboembolism by cancer type: a network meta-analysis. Semin Thromb Hemost 2024; 50 (03) 328-341
- 43 Kershaw G. Strategies for performing factor assays in the presence of emicizumab or other novel/emerging hemostatic agents. Semin Thromb Hemost 2024; 50 (08) 1163-1172
- 44 Franchini M, Focosi D. Innovative therapies for acquired hemophilia A. Semin Thromb Hemost 2025; 51 (01) 68-72
- 45 Saadalla A, Seheult J, Pruthi RK, Chen D. Von Willebrand factor multimer analysis and classification: a comprehensive review and updates. Semin Thromb Hemost 2023; 49 (06) 580-591
- 46 Bala NS, Thornburg CD. Gene therapy in hemophilia A: achievements, challenges, and perspectives. Semin Thromb Hemost 2025; 51 (01) 28-40
- 47 Tufano A, Brenner B. Prevention of venous thromboembolism in medical patients with thrombocytopenia or with platelet dysfunction: the last 10 years. Semin Thromb Hemost 2024; 50 (01) 96-103
- 48 Lippi G, Favaloro EJ. Pearls and pitfalls in the measurement of direct oral anticoagulants. Semin Thromb Hemost 2024; 50 (08) 1114-1122
- 49 Dorgalaleh A. The history of factor XIII deficiency. Semin Thromb Hemost 2024; 50 (01) 34-42
- 50 Valerio L, Baddour LM. Septic pulmonary embolism: a contemporary profile. Semin Thromb Hemost 2023; 49 (08) 840-847
- 51 Woods AI, Paiva J, Dos Santos C, Alberto MF, Sánchez-Luceros A. From the discovery of ADAMTS13 to current understanding of its role in health and disease. Semin Thromb Hemost 2023; 49 (03) 284-294
- 52 Giuffrida AC, Siboni SM, Baronciani L, Poli G, Gandini G, Peyvandi F. Emicizumab in type 3 von Willebrand disease: report of a case with an alloantibody and literature review. Semin Thromb Hemost 2025; 51 (01) 73-80
- 53 Ljung R. Prophylactic treatment of children with hemophilia in Sweden. Semin Thromb Hemost 2024; 50 (05) 714-719
- 54 Nogami K. Clot waveform analysis for monitoring hemostasis. Semin Thromb Hemost 2023; 49 (06) 592-599
- 55 Warren BB, Moyer GC, Manco-Johnson MJ. Hemostasis in the pregnant woman, the placenta, the fetus, and the newborn infant. Semin Thromb Hemost 2023; 49 (04) 319-329
- 56 Iba T, Connors JM, Levy JH. What role does microthrombosis play in long COVID?. Semin Thromb Hemost 2024; 50 (04) 527-536
- 57 Willems RAL, Biesmans C, Campello E. et al. Cellular components contributing to the development of venous thrombosis in patients with pancreatic cancer. Semin Thromb Hemost 2024; 50 (03) 429-442
- 58 Malinowski AK, Abdul-Kadir R. planning pregnancy and birth in women with inherited bleeding disorders. Semin Thromb Hemost 2023; 49 (04) 371-381
- 59 Gelbenegger G, Buchtele N, Schoergenhofer C. et al. Disseminated intravascular coagulation in anaphylaxis. Semin Thromb Hemost 2024; 50 (04) 569-579
- 60 Andersson NG, Kenet G. Intracranial hemorrhages in neonates: incidence, risk factors, and treatment. Semin Thromb Hemost 2023; 49 (04) 409-415
- 61 Favaloro EJ, Pasalic L, Lippi G. Maintaining hemostasis and preventing thrombosis in coronavirus disease 2019 (COVID-19)-part IV. Semin Thromb Hemost 2023; 49 (01) 3-8
- 62 Smock KJ, Gosselin RC. Laboratory diagnostics for thrombosis and hemostasis testing-part II. Semin Thromb Hemost 2023; 49 (06) 569-570
- 63 Favaloro EJ. Celebrating 50 years of seminars in thrombosis and hemostasis-part III. Semin Thromb Hemost 2024; 50 (01) 4-7
- 64 Smock KJ, Moffat KA. Laboratory diagnostics for thrombosis and hemostasis testing-part III. Semin Thromb Hemost 2024; 50 (08) 1047-1048
- 65 Favaloro EJ. Celebrating 50 years of seminars in thrombosis and hemostasis-part IV. Semin Thromb Hemost 2024; 50 (05) 677-681
- 66 Favaloro EJ. Celebrating 50 years of seminars in thrombosis and hemostasis-part II. Semin Thromb Hemost 2023; 49 (03) 212-216
- 67 Schulman S. Recent advances in thrombosis and hemostasis-part X. Semin Thromb Hemost 2024; 50 (06) 807-808